Treatment for chronic depression using Cognitive Behavioral Analysis System of Psychotherapy (CBASP)

McCullough, James P.

doi:10.1002/jclp.10176

Cited by 182 publications

(113 citation statements)

References 11 publications

(18 reference statements)

Supporting

Mentioning

102

Contrasting

Unclassified

Order By: Relevance

“…98 patients met criteria for assignment to one of the 4 treatment groups (phase II): 1) Lithium-augmentation (LiAugm), 2) switch of antidepressants (AD-Switch), 3) combination of antidepressants (AD-Comb), 4) augmentation with SGA (SGA-Augm). Criteria for enrolment into analysis were: patients had to have an adequate antidepressant monotherapeutic treatment in phase I according to duration (21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35) To assess the severity of depressive symptoms, clinician-rated and self-rating instruments were used at admission and at discharge (t1 and t2). Treatment groups were as heterogeneous as they normally appear in clinical practice.…”

Section: Assignmentmentioning

confidence: 99%

Comparing Augmentation with Non-Antidepressants over Sticking to Antidepressants after Treatment Failure in Depression: A Naturalistic Study

Köhler

Unger²,

Hoffmann³

et al. 2012

Pharmacopsychiatry

View full text Add to dashboard Cite

Introduction: Non-response to an antidepressant monotherapy in unipolar depression is quite common. Therefore strategies for subsequent treatment steps are necessary. However, there is a lack of direct comparisons of these different strategies. In this naturalistic study we compared the outcome to different strategies after failure of the primary antidepressant treatment. Methods: Failure of primary antidepressant monotherapy occurred in 135 patients. 98 of these patients have been administered 4 treatment strategies of the physicians? choice: lithium augmentation (Li-Augm), switching to another antidepressant (AD-Switch), combination of 2 antidepressants (AD-Comb) or augmentation with second generation antipsychotic (SGA-Augm). Primary outcome measure was the 17-item Hamilton rating scale for depression (HRSD). Results: Patients who received Li-Augm or augmentation with SGAs showed significantly greater improvement in HRSD and BDI compared to patients with antidepressant switch or antidepressant combination. Remission rates for Li-Augm and SGA-Augm were 89.3% and 86.2% compared to 40.7% for AD-Switch and 42.9% for AD-Comb. Discussion: Changing to another pharmacological class (Li-Augm or augmentation with SGAs) showed better treatment results than sticking to the class of antidepressants (AD-Switch and AD-Comb) after primary failure in response to antidepressant monotherapy in unipolar depression. The lack of randomization and absence of a non-response definition are design flaws. Controlled studies are required to confirm the findings of this trial.

show abstract

Section: Assignmentmentioning

confidence: 99%

Comparing Augmentation with Non-Antidepressants over Sticking to Antidepressants after Treatment Failure in Depression: A Naturalistic Study

Köhler

Unger²,

Hoffmann³

et al. 2012

Pharmacopsychiatry

View full text Add to dashboard Cite

show abstract

“…Childhood adversity has also been related to higher likelihood of relapse after initial remission of depression (Lara et al, 2000). We recently evaluated whether the presence or absence of ELS might moderate treatment responses of patients with chronic depression to either pharmacological treatment (nefazodone) or psychotherapy (Cognitive Behavioral Analysis System of Psychotherapy; see McCullough, 2003), or the combination of both . Overall, the effects of the antidepressant alone and psychotherapy alone were equal and significantly less effective than combination treatment (Keller et al, 2000).…”

Section: Els and The Treatment Response In Depressionmentioning

confidence: 99%

Importance of Studying the Contributions of Early Adverse Experience to Neurobiological Findings in Depression

Heim

Plotsky

Nemeroff

2004

Neuropsychopharmacol

471

339

View full text Add to dashboard Cite

Almost four decades of intensive research have sought to elucidate the neurobiological bases of depression. Epidemiological studies have revealed that both genetic and environmental factors contribute to the risk for depression. Adverse early-life experiences influence neurobiological systems within genetic limits, leading to the neurobiological and behavioral manifestations of depression. We summarize the burgeoning evidence concerning a pre-eminent role of early adverse experience in the pathogenesis of depression. The available data suggest that (1) early adverse experience contributes to the pathophysiology of depression, (2) there are neurobiologically different subtypes of depression depending on the presence or absence of early adverse experience, likely having confounded previous research on the neurobiology of depression, and (3) early adverse experience likely influences treatment response in depression. Classification of depression based on developmental and neurobiological features will likely considerably improve future research in the field of depression, and might lead to optimized treatment strategies that directly target different neurobiological pathways to depression.

show abstract

“…"Third wave" cognitive behavioral therapies represent one underexplored subset of treatment approaches. Specifically, the Cognitive Behavioral Analysis System of Psychotherapy (CBASP) [51,52] has demonstrated effectiveness in treating chronic depression, demonstrating effects equal to antidepressant medications as well as enhancing the effects of pharmacotherapy [6,7]. CBASP has yet to be studied in a large trial with persons with co-occurring alcohol dependence and chronic depression.…”

Section: Cbasp For Chronically Depressed Alcohol Dependent Individualsmentioning

confidence: 99%

“…Of note, the majority of so-called "third wave" cognitive behavioral therapies have not yet been rigorously studied for this specific population of chronically depressed alcohol dependent individuals. Specifically, Cognitive Behavioral Analysis System of Psychotherapy (CBASP) has demonstrated effectiveness in treating chronic depression [6,7], but has not yet been studied in a large trial with persons with cooccurring alcohol dependence and chronic depression. Therefore, the purpose of this chapter is to discuss the therapeutic model of CBASP and the rationale for its proposed use in treating chronic depression and alcohol dependence concurrently.…”

Section: Introductionmentioning

confidence: 99%

Co-Occurring Chronic Depression and Alcohol Dependence: A Novel Treatment Approach

Kim¹,

Christopher²,

König³

et al. 2013

Psychiatric Disorders - New Frontiers in Affective Disorders

View full text Add to dashboard Cite

Treatment for chronic depression using Cognitive Behavioral Analysis System of Psychotherapy (CBASP)

Cited by 182 publications

References 11 publications

Comparing Augmentation with Non-Antidepressants over Sticking to Antidepressants after Treatment Failure in Depression: A Naturalistic Study

Comparing Augmentation with Non-Antidepressants over Sticking to Antidepressants after Treatment Failure in Depression: A Naturalistic Study

Importance of Studying the Contributions of Early Adverse Experience to Neurobiological Findings in Depression

Co-Occurring Chronic Depression and Alcohol Dependence: A Novel Treatment Approach

Contact Info

Product

Resources

About